EEP-LEGAL
8.1.2021 17:03:29 CET | Business Wire | Press release
Netherlands-owned Reggeborgh , has assumed control of 95% of Greek tolls by monopolising multiple Greek markets and defying EU competition regulations. Reggeborgh has acquired minority shares in Gek Terna Group and Ellaktor Group , Greece’s two leading business groups in the Construction, Renewable Energy, and Concessions (Handling, Maintenance and Operation of Toll Motorways). By controlling these companies, Reggeborgh stands to benefit from 32 billion euros of Covid-19 emergency relief funding which is being redirected into the country’s infrastructure, renewables, and construction.
In response, Ellaktor minority shareholder Mr. Michail Koulas has filed a complaint with the European Commission Directorate-General for Competition . According to the Complaint, dated 31.12.2020, Reggeborgh - parent company of Dutch Construction/Real Estate Market Leader VolkerWessels - follows a strategy of monopolization of Greek Construction, Renewable Energy Sources, and the Concession markets. Reggeborgh acquired the majority shares in Gek Terna (31% since March 2019) and Ellaktor (27% since December 2020). Considering low participation levels in both companies' General Assemblies REGGEBORGH now controls their decision making and management. Reggeborgh now has control of more than 95% of the Concessions market (Handling, Maintenance and Operation of Toll Motorways).
Mr. Koulas’s complaint details Reggeborgh's anti-competitive practice of abusing its market dominance to extinguish competition in breach of European Union competition law. Reggeborgh has illegally created a dominant and super-dominant position in segments and subsegments (Markets and Submarkets) crucial for consumer wellbeing and distorts competition in the Greek Geographical Market more widely.
According to Mr Koulas, his intent is:
“To ensure that the concentration at hand is duly examined by the competent competition authorities. Minority shareholders find themselves trapped in a Shareholder Pattern that has not been cleared by competent authorities. Competition and antitrust laws have to be enforced since they are designed to ensure that dominant companies – like the Dutch behemoth REGGEBORGH – are not allowed to foreclose competition illegally. We’re asking the EU to be a neutral party that will examine the facts and enforce the law.”
Ioannis Papanastasopoulos (Attorney at Law, Managing Partner of EEP Legal ) said:
"The case has been referred to the Competent Authorities i.e. Directorate General Competition and we expect its immediate action and scrutiny. The subject under examination is rather sensitive, since 32 billion euros of emergency/relief fund for Covid 19 for Greece will be channeled to Greek infrastructure renewables and construction markets.”
Emmanouil Margomenos (Attorney at Law) senior legal counsel for the team instructed to file the complaint said:
“There are obvious implications involved to the GEK TERNA / ELLAKTOR acquisition and concentration to a single undertaking. Those two market leaders becoming one entity under single control of REGGEBORGH results in REGGEBORGH controlling every single kilometre of toll motorway in Greece.”
The European Commission is already reviewing the complaint and will decide whether to open a formal investigation into Reggeborgh ’s anti-competitive practices.
Ioannis Papanastasopoulos,
EEP LEGAL, MANAGING PARTNER
View source version on businesswire.com: https://www.businesswire.com/news/home/20210108005397/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mosaic Therapeutics to Present Poster Highlighting Preclinical Data for Lead Program MOS101 at the American Association for Cancer Research (AACR) Annual Meeting 202624.3.2026 09:30:00 CET | Press release
First preclinical data on the Company’s lead program MOS101: a combination of ASTX295, a next-generation, clinical-stage MDM2 antagonist, and olaparib, an FDA-approved PARP inhibitor, in biomarker-selected solid tumorsAdditional data showcasing Mosaic’s Discovery Platform, PRIME, will be presented Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced it will hold a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego, CA. Poster Presentation Details: Title: "Combination of the MDM2 antagonist ASTX295 and olaparib as a novel treatment option for BRCA2 mutant, TP53 wild-type solid tumors” Abstract Number: 3053 Date and Time: Monday, April 20, 2026, 2:00PM – 5:00PM PST Session Category: Novel Targets and Pathways Session: PO.ET09.09 Location: Poster Section 15 For more information an
Vonage and ServiceNow Expand their Partnership24.3.2026 09:20:00 CET | Press release
Vonage Contact Center with ServiceNow Voice integrates enterprise-grade voice and AI capabilities directly into enterprise workflows, boosting agent productivity and customer engagement Vonage, part of Ericsson (NASDAQ: ERIC), today announced the launch of its native integration with ServiceNow Voice, built on the ServiceNow AI Platform, embedding enterprise-grade voice and real-time AI capabilities directly into ServiceNow Customer Service Management (CSM) and IT Service Management (ITSM) workflows for Vonage Contact Center (VCC) customers. Vonage provides a unified service environment for enterprise customer service and IT support teams, enabling agents to deliver exceptional customer experiences while driving improvements to service performance. The integration of VCC with ServiceNow embeds real-time voice and AI capabilities into enterprise workflows, giving them the tools their agents need to streamline case progression, automate workflows, and reduce manual effort. Through the Vo
Omnes Partners With Apex Group to Tokenise Institutional Bitcoin Mining Structured Note on Base24.3.2026 09:00:00 CET | Press release
Omnes today announced a strategic partnership with Apex Group, a leading global financial services provider with over $3.5 trillion in assets serviced, to tokenise its flagship Omnes Mining Note "OMN". The OMN is an institutional grade structured note backed by Bitcoin hashrate, to be issued and managed on the Base Chain, the Ethereum L2 incubating at Coinbase, leveraging Apex Digital 3.0 for comprehensive tokenisation, administration, and transfer agency services as a fully integrated end to end solution. The OMN provides professional non-US investors with direct economic exposure to new Bitcoin production measured in hashrate, which is the computational power used to validate transactions and produce Bitcoin, without the operational complexities of managing mining infrastructure, hardware, energy, or regulatory hurdles. Issued as a secured debt note in Luxembourg, the tokenised OMN combines traditional financial structuring with blockchain enabled features, including on chain transfe
Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 07:00:00 CET | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 07:00:00 CET | Press release
From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio® (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF® (trifarotene)1-8 Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil® in different skin types9 Data from Galderma’s Injectable Aesthetics portfolio will also show how its hyaluronic acid injectables, Restylane®, and neuromodulator, RelabotulinumtoxinA*, may address aesthetic needs across the face and décolletage10-14 A total of 22 presentations will reinforce the value of Galderma’s broad and comprehensive portfolio in meeting varied patient needs across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare Galderma (SIX: GALD), the pure-play dermatology category leader, wi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
